Characteristics of Patients treated with Immunotherapy alone or in combination with other therapies

The AIET has been administered with and without combination of other treatments in Lung cancer, Breast cancer, Stomach cancer, Uterus cancer, Head and neck cancer, Liver cancer, Prostate cancer, Rectal cancer, Esophagus cancer, Malignant melanoma(1), Multiple myeloma (2).

A male patient aged 40 years with Stage III (advanced) adenocarcinoma of the pancreas was given three transfusions of expanded NK and Cytotoxic T Lymphocytes along with surgery and adjuvant chemotherapy by NCRM. There was considerable improvement in the quality of life of the patient after the first transfusion which made the patient to take two more cycles of the AIET. The patient showed steady improvement with a significant tumor response proven by a steady decrease in tumour marker CA 19-9 values from 3800 -750 and a tumour progression-free survival of 18 months (3)

In one study 28 patients with inoperable advanced tumour of pancreas Immuno-cell therapy was given along with chemotherapy and these patients had a 50% survival time of 15.8 months(4)

Forty-four patients with stage IV gastric cancer assigned to the control group (chemotherapy alone) or immunotherapy plus chemotherapy group. The 50% survival rates were 11.5 and 8.3 months in the Immunotherapy and control groups, respectively (5)

  1.  Goto et al., Clinical benefit of non-toxic therapy in patients with advanced cancer (opinion). Anticancer Res. 2002
  2. Sharat Damodar, Terunuma H, Sheriff AK, Farzana L, Manjunath S, Senthilkumar R, Shastikumar G, Abraham S “Autologous Immune Enhancement Therapy (AIET) for a Case of Acute Myeloid Leukemia (AML) - Our Experience”; PASRM 2006
  3. Sivaraman G, Pandian A,Baskar S, Senthil KR, Senthilnagarajan R, Dedeepiya V, Abraham S, “Autologous Immune Enhancement therapy for advanced carcinoma of pancreas a case report”, PASRM, III annual symposium , 2008
  4. Toru Kaneko, Shigenori Goto, Akira Kato, Akiteru Akeyama3, Masamichi Tomonaga, Katsunada Fujimoto, Yoju Miyamoto, Masazumi Eriguchi and Koji Egawa. Efficacy of immuno-cell Therapy in patients with Advanced Pancreatic Cancer. Anticancer Research 25: 3709-3714(2005)
  5. Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res. 2002;8(6):1767-71..